Comprehensive Genomic Profiling of Diagnostic Bone Marrow Specimens Identifies Mutational Profiles Predictive of Relapse in Patients with Acute Myeloid.

Slides:

Advertisements

Similar presentations

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J

Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic.

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation Filippo Milano, MD, PhD, Brent.

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia

Analysis of the Prognostic Effect of Peripheral Blood Lymphocyte and Monocyte Count after Autologous Hematopoietic Stem Cell Transplant in Refractory/Relapsed.

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors Jo-Anne H. Young, MD, Brent R. Logan,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Biology of Blood and Marrow Transplantation

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Nicholas E. Khan, Philip S. Rosenberg, Blanche P. Alter

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Low-Dose Azacitidine (AZA) for Treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapse after Allogeneic Hematopoietic Cell.

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia George L. Chen, Hong Liu,

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Emerging Importance of Mutational Analysis in Myelodysplastic Syndrome and Acute Myelogenous Leukemia Aaron T. Gerds, Matthew J. Walter, Bart L. Scott

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic.

Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.

Infusion of Autograft Natural Killer Cells/CD14+hla-DRDIM Myeloid-Derived Suppressor Cells Ratio Predicts Survival in Non-Hodgkin Lymphoma Undergoing.

Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.

Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or.

Early CD4+ Immune Reconstitution Predicts Probability of Relapse in Pediatric AML after Unrelated Cord Blood Transplantation: Importance of Preventing.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Early Response to Initial Induction Chemotherapy in Acute Myeloid Leukemia (AML) and Outcomes after Allogeneic Hematopoietic Cell Transplant (HCT) Masumi.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Biology of Blood and Marrow Transplantation

Myeloid Derived Suppressor Cells (MDSC)-like Acute Myeloid Leukemia (AML) Cells Are Associated with Resistance to Cytotoxic Effects of Autologous (Auto)

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.

Reduced Intensity Versus Myeloablative Conditioning Allogeneic HCT for Relapsed/Refractory Lymphoma: Applying Refined Disease Risk Index (DRI) to Improve.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Heather A. Himburg, PhD, Liman Zhao, Jenny Kan, John P. Chute, M.D.

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Treatment versus Transplant for Challenging Hematologic Disorders

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Mary Eapen Biology of Blood and Marrow Transplantation

Presentation transcript:

Comprehensive Genomic Profiling of Diagnostic Bone Marrow Specimens Identifies Mutational Profiles Predictive of Relapse in Patients with Acute Myeloid Leukemia Who Undergo Autologous Hematopoietic Cell Transplantation Gabriel N. Mannis, MD, Shan Zhong, PhD, Michelle Nahas, PhD, Lily Kahira, MS, Aaron C. Logan, MD, PhD, Charalambos Andreadis, MD, MSCE, Lloyd E. Damon, MD, Rebecca L. Olin, MD, MSCE, Sohail Balasubramanian, MS, Jie He, PhD, Jo-Anne Vergilio, MD, Tariq Mughal, MD, Weiyun Ai, MD, PhD, Karin M.L. Gaensler, MD, Peter Sayre, MD, Jeffrey L. Wolf, MD, Thomas G. Martin, MD Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S41-S42 (March 2016) DOI: 10.1016/j.bbmt.2015.11.322 Copyright © 2016 Terms and Conditions

Figure 1 (A,B) Mutational profiles of relapsers versus non-relapsers in (A) intermediate-risk AML and (B) favorable-risk AML. (C) Relapse-free survival (RFS) of patients with favorable- versus intermediate-risk cytogenetics who underwent autologous hematopoietic cell transplant (autoHCT) for acute myeloid leukemia (AML). Time truncated at 6yrs for clarity. (D) RFS stratified by the presence of the following alterations: FLT3- ITD, NRAS, MLL, or IDH1/2. Time truncated at6yrs for clarity. Biology of Blood and Marrow Transplantation 2016 22, S41-S42DOI: (10.1016/j.bbmt.2015.11.322) Copyright © 2016 Terms and Conditions